Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;39(5):1247-1251.
doi: 10.1038/s41375-025-02555-0. Epub 2025 Apr 1.

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study

Lucile Bussot  1 , Stéphanie Poulain  2   3 , Morgane Nudel Ortmans  4 , Frédéric Davi  5 , Damien Roos-Weil  6 , Stéphane Lepretre  7 , Doriane Richard  7 , Cédric Pastoret  8 , Anne Desmares  8 , Emmanuelle Ferrant  9 , Sarah Huet  9 , Pierre Sujobert  9 , Eric Delabesse  10 , Loïc Ysebaert  10 , Grégory Lazarian  11 , Anne-Sophie Michallet  12 , Audrey Bidet  13 , Marie Sarah Dilhuydy  13 , Marie-Hélène Delfau-Larue  14   15 , Jehan Dupuis  16 , Aline Clavert  17 , Bernard Drenou  18 , Elsa Maitre  19 , Xavier Troussard  19 , Edouard Cornet  19 , Yannick Le Bris  20 , Anne Lok  20 , Bruno Villemagne  21 , Hélène Barbier  21 , Marie C Béné  20 , Cécile Tomowiak  22 , Stéphanie Tardy  23 , Pascale Cornillet-Lefebvre  24 , Anne Quinquenel  24 , Romain Guièze  25 , Sarah Barbieux  26 , Isabelle Plantier  27 , Julia Hieulle  27 , Pascale Flandrin Gresta  28 , Jérôme Cornillon  28 , Sophie Dupire  29 , Kamel Laribi  30 , Pierre Feugier  31 , Caroline Algrin  32 , Florence Lachenal  33 , Adrien Caillet  34 , Anne Murati  35 , Luca Inchiappa  35 , Céline Lechat  30 , Caroline Dartigeas  36 , Émilie Montaut  37 , Lysiane Molina  1 , Sylvain Carras  38   39   40
Affiliations

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study

Lucile Bussot et al. Leukemia. 2025 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: LB: Consultancy; AstraZeneca, Janssen-Cilag, Beigene, Abbvie; research grants; AstraZeneca, Janssen-Cilag, DR-W: Consultancy: Abbvie, AstraZeneca, BeiGene, Janssen-Cilag, GL: Consultancy; AstraZeneca, Janssen-Cilag, Beigene, AC: Consultancy: AstraZeneca, Janssen-Cilag, Abbvie, XT: Consultancy: Abbvie, AL: Consultancy: Janssen-CilagCT: Consultancy: Janssen-Cilag, BeiGene, AstraZeneca, Abbvie, JH: Consultancy: Novartis, Abbvie, AstraZeneca, Servier, JC: Consultancy: Janssen-Cilag, Takeda and JazzPharma. Travel grants: MSD, Gilead, Novartis, Janssen-Cilag, Pfizer; Sandoz, Abbvie, SC: Consultancy and travel grants; AstraZeneca, Janssen-Cilag, Beigene, Abbvie; research grants; AstraZeneca, Janssen-Cilag.

Figures

Fig. 1
Fig. 1. Outcomes of patients after a first line of treatment.
Kaplan–Meier estimator of PFS; A Whole cohort according to S#2/nS#2 and treatment strategies (CIT vs TT), B patients treated by CIT according to S#2/nS#2 and IGHV status, C patients treated by TT according to S#2/nS#2 status, D patients treated by BTKi according to S#2/nS#2 and IGHV status, E nS#2 patients treated by CIT or TT, F S#2 patients treated by CIT or TT, G nS#2 patients treated by CIT, BTKi or BCL2i, H S#2 patients treated by CIT, BTKi or BCL2i.
See this image and copyright information in PMC

References

    1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–48. - PMC - PubMed
    1. Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1:e74–84. - PubMed
    1. Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015;125:856–9. - PMC - PubMed
    1. Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, et al. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 2019;104:360–9. - PMC - PubMed
    1. Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, et al. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica. 2018;103:e158–61. - PMC - PubMed

LinkOut - more resources